Enrolling by invitationPhase 2NCT06961344
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
Studying MELAS
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tisento Therapeutics
- Intervention
- zagociguat 15mg(drug)
- Enrollment
- 44 enrolled
- Eligibility
- All sexes
- Timeline
- 2025 – 2028
Study locations (15)
- UC San Diego - Altman Clinical and Translational Research Institute, La Jolla, California, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Rare Disease Research, Atlanta, Georgia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mount Sinai - Ichan School of Medicine, New York, New York, United States
- Akron Children's Hospital, Akron, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Baylor College of Medicine, Houston, Texas, United States
- UT Health Houston, Houston, Texas, United States
- Neuroscience Research Australia, Sydney, New South Wales, Australia
- Royal Melbourne Hospital, Melbourne, Victoria, Australia
- LMU Klinikum, Friedrich-Baur-Institute, Department of Neurology, Munich, Germany
- Neurologic Institute Carlo Besta of Milan, Milan, Italy
- University College London Hospital. The National Hospital for Neurology and Neurosurgery, Centre for Neuromuscular Diseases, London, United Kingdom
- The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06961344 on ClinicalTrials.govOther trials for MELAS
Additional recruiting or active studies for the same condition.